Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Bristol-Myers, KAI Link For Heart Drug

May 19, 2008 | A version of this story appeared in Volume 86, Issue 20

Bristol-Myers Squibb has signed an agreement to develop and commercialize a heart drug from the California biotechnology firm KAI Pharmaceuticals. BMS will pay KAI $25 million upfront and up to $192 million in milestone payments. It may also buy $10 million of KAI stock if the firm holds an initial public offering. The drug, KAI-9803, is an isozyme-selective inhibitor of the delta protein kinase C pathway and is designed to reduce the deleterious effects of a heart attack. It is expected to enter Phase IIb clinical trials by the end of the year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.